Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.
COVID-19
Clinical trial
Convalescent plasma
Hospital stay
Mortality rate
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
25
06
2020
revised:
06
07
2020
accepted:
06
07
2020
pubmed:
23
7
2020
medline:
15
12
2020
entrez:
23
7
2020
Statut:
ppublish
Résumé
Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.
Identifiants
pubmed: 32694043
pii: S1473-0502(20)30180-4
doi: 10.1016/j.transci.2020.102875
pmc: PMC7362821
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Pagination
102875Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
J Clin Invest. 2020 Sep 1;130(9):4791-4797
pubmed: 32525844
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
J Clin Virol. 2020 Jun;127:104388
pubmed: 32361326
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Vox Sang. 2020 Aug;115(6):488-494
pubmed: 32240545
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Emerg Infect Dis. 2016 Sep;22(9):1554-61
pubmed: 27532807
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Infect Control Hosp Epidemiol. 2020 Jun;41(6):754-755
pubmed: 32192541
Hematol Transfus Cell Ther. 2020 Apr - Jun;42(2):113-115
pubmed: 32313872
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Transfus Med Rev. 2020 Jul;34(3):145-150
pubmed: 32359788
Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):3-6
pubmed: 32534509
Ann Intern Med. 2006 Oct 17;145(8):599-609
pubmed: 16940336
J Korean Med Sci. 2020 Apr 13;35(14):e149
pubmed: 32281317
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
J Clin Virol. 2020 Jun;127:104378
pubmed: 32353762
JAMA. 2020 Apr 28;323(16):1561-1562
pubmed: 32219429